Literature DB >> 8877030

Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus.

K S Lam1, M S Wat, K L Choi, T P Ip, R W Pang, C R Kumana.   

Abstract

1. The pharmacokinetics and pharmacodynamics of intranasal (IN) and oral 1-deamino-8-D-arginine vasopressin (DDAVP) were compared in 10 Chinese adults with central diabetes insipidus previously controlled on IN DDAVP. This was followed by comparison of the acute pharmacodynamics of commonly used oral preparations (containing 100, 200 and 400 micrograms per tablet) and a 1 year prospective evaluation of the long-term safety and efficacy of oral DDAVP. 2. Following 20 micrograms IN and 200 micrograms orally, respective plasma DDAVP concentrations peaked after 45.6 +/- 7.3 and 93.3 +/- 3.3 (mean +/- s.e.mean) min, reaching 24.1 +/- 4.7 and 15.1 +/- 3.2 pmol 1(-1) and respective terminal half-lives were 2.2 +/- 0.1 and 2.0 +/- 0.1 h. Based on the area under the concentration-time-curve, the bioequivalent IN/oral ratio was 1:16. 3. As judged by changes in urine flow rate and osmolality after IN or oral (100, 200 or 400 micrograms) DDAVP, antidiuretic activity increased rapidly during the second hour and peaked at 4 h. The antidiuresis duration and magnitude correlated with the oral dose (P < 0.001 and < 0.05 respectively), and was least following 100 micrograms (P < 0.01 vs 200 or 400 micrograms). Increasing the dose from 200 to 400 micrograms did not increase maximal antidiuretic activity significantly, but there was a trend towards a longer duration of action (P = 0.076). 4. During the 1-year prospective study with oral DDAVP 300-600 micrograms per day in two to three doses, stable and satisfactory antidiuresis (comparable with that on previous IN therapy) was maintained; tablets were well-tolerated and no side-effect warranted drug withdrawal. 5. These findings suggest that the 100 and 200 micrograms preparations of oral DDAVP are adequate for the long-term control of central diabetes insipidus in our population, and that the 400 micrograms preparation may have a role if the frequency of administration is to be reduced.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877030      PMCID: PMC2042683          DOI: 10.1046/j.1365-2125.1996.39914.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.

Authors:  Asa Rembratt; Charlotte Graugaard-Jensen; Thomas Senderovitz; Jens Peter Norgaard; Jens Christian Djurhuus
Journal:  Eur J Clin Pharmacol       Date:  2004-06-09       Impact factor: 2.953

2.  Desmopressin duration of antidiuretic action in patients with central diabetes insipidus.

Authors:  Kristian Vinter Juul; Daniel G Bichet; Jens Peter Nørgaard
Journal:  Endocrine       Date:  2011-05-29       Impact factor: 3.633

Review 3.  Desmopressin therapy in children and adults: pharmacological considerations and clinical implications.

Authors:  Xinyi Chin; Shao Wei Teo; Soo Ting Lim; Yong Hong Ng; How Chuan Han; Fabian Yap
Journal:  Eur J Clin Pharmacol       Date:  2022-02-23       Impact factor: 2.953

Review 4.  Diagnosis and Management of Central Diabetes Insipidus in Adults.

Authors:  Maria Tomkins; Sarah Lawless; Julie Martin-Grace; Mark Sherlock; Chris J Thompson
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

5.  3T renal (23)Na-MRI: effects of desmopressin in patients with central diabetes insipidus.

Authors:  Stefan Haneder; Henrik J Michaely; Simon Konstandin; Lothar R Schad; John N Morelli; Bernhard K Krämer; Stefan O Schoenberg; Alexander Lammert
Journal:  MAGMA       Date:  2013-04-06       Impact factor: 2.310

6.  A case of idiopathic diabetes insipidus presented with bilateral hydroureteronephrosis and neurogenic bladder: A pediatric case report and literature review.

Authors:  Ozgur Haki Yuksel; Mithat Kivrak; Aytac Sahin; Serkan Akan; Ahmet Urkmez; Ayhan Verit
Journal:  Can Urol Assoc J       Date:  2015-11-04       Impact factor: 1.862

7.  Management of diabetes insipidus in children.

Authors:  Garima Mishra; Sudha Rao Chandrashekhar
Journal:  Indian J Endocrinol Metab       Date:  2011-09

Review 8.  Diabetes insipidus: The other diabetes.

Authors:  Sanjay Kalra; Abdul Hamid Zargar; Sunil M Jain; Bipin Sethi; Subhankar Chowdhury; Awadhesh Kumar Singh; Nihal Thomas; A G Unnikrishnan; Piya Ballani Thakkar; Harshad Malve
Journal:  Indian J Endocrinol Metab       Date:  2016 Jan-Feb

Review 9.  Diabetes Insipidus after Traumatic Brain Injury.

Authors:  Cristina Capatina; Alessandro Paluzzi; Rosalid Mitchell; Niki Karavitaki
Journal:  J Clin Med       Date:  2015-07-13       Impact factor: 4.241

Review 10.  Diabetes insipidus: a challenging diagnosis with new drug therapies.

Authors:  Chadi Saifan; Rabih Nasr; Suchita Mehta; Pranab Sharma Acharya; Isera Perrera; Giovanni Faddoul; Nikhil Nalluri; Mayurakhan Kesavan; Yorg Azzi; Suzanne El-Sayegh
Journal:  ISRN Nephrol       Date:  2013-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.